{"text": "TITLE:\n      Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO\u00ae, JESPECT\u00ae) in a Pediatric Population in Non-endemic Countries\nSUMMARY:\n      The primary objective is to assess the safety profile of IC51 in a pediatric population from\n      regions where JEV is not endemic\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          -  Male or female healthy children and adolescents aged >=2 months to <18 years at the\n             time of first vaccination\n          -  Written informed consent by the subject's legal representative(s), according to local\n             requirements, and written informed assent of the subject, if applicable\n          -  Female subjects: either no childbearing potential or negative pregnancy test. For\n             females after menarche willingness to practice a reliable method of contraception.\n          -  The subject is planning to travel to an area where JE is endemic after completion of\n             the vaccination schedule. Exposure to JE should be avoided until 1 week after the\n             second IC51 dose and subjects should return from travel to JE endemic areas before\n             the Month 7 visit. The planned travel to JE endemic areas should not interfere with\n             the study visits and can take place between Visit 2 + 7 days to Month 7.\n        Exclusion Criteria:\n          -  Clinical manifestation or history of any Flavivirus disease\n          -  Vaccination against JE (except within this protocol), Yellow fever, West Nile virus\n             and Dengue at any time prior or during the study\n          -  History of immunodeficiency or immunosuppressive therapy\n          -  Known HIV, HBV or HCV infection\n          -  History of hypersensitivity reactions to other vaccines\n          -  Acute febrile infection at each visit during which the subject receives a vaccination\n          -  Active or passive immunization within 1 week before and 1 week after each IC51\n             vaccination.\n", "cuis": "C0771080 C3536988 C0014057 C0876889 C0587599 C1951312 C0220644 C1552616 C1706244 C0018017 C2239270 C2979883 C0876889 C0220644 C0220645 C0243161 C0013893 C0243161 C0686744 C1561542 C0042196 C2713304 C0058773 C0419749 C0009797 C0973449 C0562357 C0556050 C0427780 C1504358 C0430057 C2222792 C0700589 C0344221 C0493327 C0877698 C0086286 C0086580 C0025274 C0237607 C3245512 C3858758 C0025663 C0025664 C0032074 C1555670 C0042196 C2713304 C0058773 C0419749 C0086960 C0274281 C0332157 C2220266 C1561540 C1555670 C1555670 C1512346 C0947630 C1512346 C0243161 C3272565 C0262926 C2004062 C0012634 C0018609 C0015411 C1096184 C3686467 C3888561 C0043395 C0301508 C0239574 C0042196 C1114735 C0442711 C1507394 C1522729 C2348563 C3715209 C0011311 C0947630 C0021079 C0455630 C0021051 C1855166 C0043194 C0221026 C0549463 C1279481 C3714976 C0262926 C2004062 C0009450 C3714514 C0275524 C0012683 C0035637 C0276041 C0729555 C0747002 C0020517 C0020522 C0301918 C1820377 C3662866 C1302878 C0042210 C0262926 C2004062 C0042196 C2713304 C0058773 C0419749 C0009450 C3714514 C0275524 C0012683 C0035637 C0276041 C0729555 C0747002 C0015967 C0277797 C1547229 C1547295 C1512346 C0020974 C0312645 C0718247 C1561540 C0042196 C2713304 C0058773 C0419749 ", "concepts": "Japanese Encephalitis Vaccines, Japanese Encephalitis Vaccine SC, Japanese Encephalitis, Pediatric, Pediatrics, Pediatrix, Pediatric HD summary, summary Objective, objective, Objective, Pediatric, pediatric HD, pediatric st criteria, Eligibility Criteria healthy child, month vaccination, Revaccinations, DT vaccination, vaccination dt informed consent form, galega Uninformed, fat requirements negative pregnancy test, False negative pregnancy test, Urine pregnancy test negative, OT potential contraception, IUD contraception, CAP contraception, CAP contraception, Contraception;F, Contraception;M, menarche, practices, practice, reliable, method, methods planning, travel vaccination, Revaccinations, DT vaccination, vaccination dt, schedule, exposure, exposure, exposure, week travel travel, visit study, Visits Criteria Clinical, history, history, disease, h disease, eye manifestation West Nile virus, West Nile virus PCR, West Nile virus test, Yellow fever NOS, yellow fever, low fever, Vaccination, Vaccination AE, Protocol, Protocol, Protocol, Protocol, Protocol Dengue, study Immunosuppressive therapy, NOS, H/O: immunosuppressive therapy, immunodeficiency, No immunodeficiency, Immunodeficiency 2, Immunodeficiency 1, Immunodeficiency 5s, Immunodeficiency 4, Immunodeficiency 14, History, History Infection, infections, Coinfections, Disinfection, RP infection, MG infection, GI infection, op infection hypersensitivity reactions, Type IV hypersensitivity reaction, Type 3 hypersensitivity reaction, Type 2 hypersensitivity reaction, Immune hypersensitivity reaction, Contact hypersensitivity reaction, vaccines, History, History vaccination, Revaccinations, DT vaccination, vaccination dt, Infection, infections, Coinfections, Disinfection, RP infection, MG infection, GI infection, op infection, febrile, Afebrile, Acute, Acute, visit passive immunizations, Passive immunization, Active, week vaccination, Revaccinations, DT vaccination, vaccination dt "}
